Fri, 23rd Oct 2020 19:39
(Recasts with confirmation)
Oct 23 (Reuters) - AstraZeneca Plc has resumed the
U.S. trial of its experimental COVID-19 vaccine after approval
by U.S. regulators, the company said on Friday.
AstraZeneca's U.S. trial was paused on Sept. 6 after
a report of a serious neurological illness, believed to be
transverse myelitis, in a participant in the company's UK trial.
(Reporting by Munsif Vengattil and Carl O'Donnell; Editing by
Anil D'Silva and Rosalba O'Brien)
PARIS, May 12 (Reuters) - Leading healthcare companies Pfizer and AstraZeneca announced on Sunday new investments in France worth a total of nearly ...
(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of Engla...
FTSE 100 up 0.5%, FTSE 250 adds 0.4% *
(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the...
(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemi...
Astrazeneca (AZN)